Regeneron Pharmaceuticals Wins Prestigious Biotech Award

Congratulations to the BCW’s esteemed life sciences member and Hall of Fame winner Regeneron Pharmaceuticals for winning the 2025 Prix Galien USA Best Biotechnology Product Award for the groundbreaking science of Dupixent (dupilumab).

The Galien Foundation, which acknowledges extraordinary scientific innovations that improve the human condition, presented the award on October 30 in New York City for the drug’s transformational impact on multiple rare and common allergic and atopic conditions.

It is the second “Best Biotechnology Product” award for Regeneron following the 2022 recognition of Inmazeb® (atoltivimab, maftivimab, and odesivimab-ebgn).

“We are honored that the Galien Foundation has recognized Dupixent, which was invented by Regeneron through decades of tireless work by our talented scientists,” said George D. Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer at Regeneron, and a principal inventor of Dupixent. “Dupixent is a true ‘first-in-class’ breakthrough that can treat multiple serious diseases and has helped re-define our understanding of allergic and atopic diseases by showing that these often disparate-appearing conditions can share the same driving mechanism of type 2 inflammation. Today, more than 1 million patients around the world are currently being treated with Dupixent.”

Dupixent has received regulatory approvals in more than 60 countries for treating certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, among other conditions.

In April, the BCW honored Regeneron Pharmaceuticals with a 2025 Hall of Fame Award for Corporate Citizenship. The company approaches corporate responsibility with three goals in mind: to improve the lives of people with serious diseases, to foster a culture of integrity and excellence and to build sustainable communities.